Opko Health Inc (OPK) Shares are Down -4.51%

Opko Health Inc (OPK) has risen sharply, recording gains of 13.51% in the past 4 weeks. However, the stock has corrected -4.51% in the past 1 week, providing a good buying opportunity on dips. On a relative basis, the stock has outperformed the S&P 500 by 14.12% in the past 4 weeks, but has underperformed the S&P 500 in the past 1 week.

The stock has recorded a 20-day Moving Average of 3.35% and the 50-Day Moving Average is 6.14%.The 200 Day SMA reached 8.35%


Opko Health Inc (NYSE:OPK): The stock opened in the green at $10.59 on Friday, but the bulls found it difficult to push the prices higher. The stock reached a high of $10.6525 and a low of $10.47 for the day. The stock did not find buyers even at the lows and closed at $10.59 recording a loss of -0.09%. 2,460,966 shares exchanged hands during the trading day. The stock had closed at $10.59 in the previous days trading.

Opko Health Inc (OPK) : 4 investment research analysts covering Opko Health Inc (OPK) have an average price target of $15 for the near short term. The highest target price given by the Brokerage Firm to the stock is $20 and the lowest target is $10 for the short term. Analysts expect the variance to be within $4.16 of the average price.

OPKO Health, Inc. (OPKO) is a biopharmaceutical and diagnostics company. The Company is involved in developing a range of solutions to diagnose, treat and prevent various conditions, including point-of-care tests, laboratory developed tests (LDTs), molecular diagnostics tests, and pharmaceuticals and vaccines. It operates in two segments: pharmaceutical and diagnostics. Its pharmaceutical segment consists of two operating segments pharmaceutical research and development segment and pharmaceutical operations. Its diagnostics segment consists of pathology operations and point-of-care and molecular diagnostics operations. It owns pharmaceutical operations in Chile, Spain, Mexico, Israel, Uruguay and Brazil. The product pipeline includes several pharmaceutical compounds and technologies in research and development for a range of indications and conditions.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *